Swiss drugmaker Novartis won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases.

Merck & Co.’s experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in late-stage trial.

At 2015’s New York Comic Con, Area 23 teamed up with Be The Match to launch The Hero Gene Lab, an effort to expand the number of people registered to be bone marrow donors. Bringing a laboratory-themed booth to the convention, Area 23 managed to get cheek swabs from about 500 people with their registry […]

Incyte Corp said on Wednesday that it would stop a mid-stage study on its combination treatment after it failed to prove to be sufficiently effective to treat metastatic colorectal cancer. The results cast a shadow on the prospects of the drug, Jakafi, which is also being studied in a late-stage trial to treat advanced pancreatic […]

U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. The U.S. Food and Drug Administration on Monday said it had approved Darzalex (daratumumab) for patients who had already undergone at least three prior standard […]

BOSTON, July 22, 2015 /PRNewswire-USNewswire/ — Using large-scale zebrafish drug-screening models, researchers at Boston Children’s Hospital have identified a potent group of chemicals that helps bone marrow transplants engraft or “take.” The findings, published in the July 23 issue of Nature, could lead to human trials in patients with cancer and blood disorders within a […]